Sponsor Investigator IDEs: When a US Physician Can Be Your Sponsor Under 21 CFR 812

The rule that stops non US companies cold

Under 21 CFR 812.18(a), a company located outside the United States cannot itself sponsor an FDA Investigational Device Exemption (IDE) study. A US person must hold the sponsor role. That is not a procedural preference; it is a hard regulatory requirement. If your device company is headquartered in Germany, Japan, South Korea, or anywhere else outside US borders, you must identify a US entity or individual who will formally take on sponsor obligations before FDA will accept your IDE application. The question is which structure fits your program, and one of the three available structures is the sponsor investigator route.

What the sponsor investigator route actually is

The sponsor investigator route is a narrow but legitimate pathway that allows a single US physician to absorb both the clinical and regulatory functions of an IDE study. Under 21 CFR 812.3(o), a 'sponsor investigator' is defined as 'an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational device is administered or used.' (21 CFR 812.3(o).) This means the physician who will treat patients is also the person who submits the IDE, communicates with FDA, files adverse event reports, maintains records, and carries every other Part 812 sponsor obligation personally.

The sponsor investigator route works best when a single academic physician at a single US institution wants to study a device in a small, investigator initiated trial. It is a recognized and workable structure in that context. The physician must be US based, must be the one actually conducting the investigation, and must be prepared to own every compliance obligation that a corporate sponsor would otherwise staff an entire regulatory affairs team to manage.

Who this route actually fits

The sponsor investigator model fits a narrow profile. It is appropriate for a single site academic study where the physician has genuine scientific ownership of the investigation, institutional support from a research office or IRB infrastructure, and the bandwidth to manage regulatory correspondence with FDA. It is not appropriate as a workaround for a non US manufacturer that simply wants to run a pivotal IDE trial through a willing physician's name. FDA reviews the substance of sponsor investigator arrangements, and an IDE program designed to gather data to support a future PMA or De Novo submission for a foreign manufacturer is not a true investigator initiated study.

It is also not the right structure for a multi site study. The moment a second investigational site is added, the administrative and oversight burden scales in ways that a single physician cannot reasonably manage alongside clinical duties. Multi site IDE programs require a corporate or institutional US sponsor of record with the infrastructure to execute monitoring, adverse event aggregation, investigator training, and device accountability across locations. Attempting to run a multi site foreign manufacturer IDE program under a sponsor investigator structure creates regulatory risk that far exceeds any perceived administrative convenience.

What the physician personally carries

Accepting the sponsor investigator designation is not a formality. The physician takes on the full scope of 21 CFR Part 812 sponsor requirements, which include preparing and submitting the IDE application, obtaining FDA approval or a determination of nonsignificant risk, preparing and updating the investigational plan, monitoring the study, reviewing and reporting unanticipated adverse device effects, maintaining required records, and submitting progress and final reports. These are the same obligations a corporate sponsor would discharge through a cross functional regulatory and clinical operations team. Any physician considering this role should review ADB's US Sponsor Obligations Checklist before accepting the designation.

The three structures and how to choose

The sponsor investigator route is one of three recognized structures for satisfying the US sponsor requirement under 21 CFR 812.18(a). The other two are a US subsidiary of the foreign manufacturer and a contract US regulatory sponsor of record. Each structure carries different liability profiles, operational implications, and suitability criteria. Before committing to any of them, it is worth using the structured decision logic in ADB's US Sponsor of Record Decision Tool to assess which structure aligns with your study design, your company's US presence, and your timeline. Making the wrong structural choice early creates rework that costs time you likely do not have.

For a fuller overview of how the US sponsor of record function works across all three structures, the ADB resource page at adbccro.com/us-sponsor provides context on FDA expectations and common points of failure.

Closing

ADB Consulting and CRO Inc. serves as US Sponsor of Record for non US medical device companies conducting FDA regulated clinical investigations in the United States. If you are working through the sponsor structure question for an IDE program and want to assess your options with an experienced regulatory team, book a free discovery call at adbccro.com. ADB's regulatory team will review your study design and help you prepare the right structure before you file.

Reviewed November 5, 2026 by ADB's regulatory team.

Frequently asked questions

Can a non US physician serve as sponsor investigator for an FDA IDE study?

No. The sponsor investigator role requires that the individual be a US person for purposes of satisfying the US sponsor requirement under 21 CFR 812.18(a). A physician located outside the United States cannot fulfill this function. The investigator may be non US in some study configurations, but the sponsor of record must be a US person or entity.

Does the sponsor investigator route work for a study that a foreign manufacturer will use to support a PMA submission?

Not without careful structural analysis. If the foreign manufacturer is driving the study design, funding the investigation, and intends to use the data for its own regulatory submission, the arrangement may not qualify as a true investigator initiated study. FDA may assess the substance of the relationship. In most cases involving a non US manufacturer seeking pivotal IDE data, a formal US sponsor of record structure is more appropriate. Use ADB's US Sponsor of Record Decision Tool to review your specific situation.

What happens if a sponsor investigator cannot keep up with the Part 812 compliance obligations mid study?

The physician remains legally responsible for all sponsor obligations until a formal transfer of sponsorship is executed and FDA is notified. Mid study sponsor transfers are possible but administratively complex and can interrupt study operations. It is far more efficient to prepare the right sponsor structure before IDE submission than to attempt a corrective transfer after the study is underway. ADB's US Sponsor Obligations Checklist can help a prospective sponsor investigator assess the full scope of what acceptance of this role requires.

If this applies to your program, our US Sponsor of Record program walks through the process in detail.